

# FINE FOODS

Sector: Industrials

# OUTPERFORM

Price: Eu7.84 - Target: Eu15.00

## Better Margin Trajectory Enhances Visibility on FY Expectations

**Giorgio Tavolini +39-02-77115.279**

giorgio.tavolini@intermonte.it

**Andrea Randone: +39-02-77115.364**

andrea.randone@intermonte.it

### Stock Rating

**Rating:** Unchanged


**Target Price (Eu):** from 17.50 to 15.00

	2022E	2023E	2024E
<b>Chg in Adj EPS</b>	-20.3%	0.0%	0.0%

### Next Event

2Q22 Results out 13 September'22

### FINE FOODS - 12M Performance



### Stock Data

Reuters code: FF.MI

Bloomberg code: FF IM

Performance	1M	3M	12M
Absolute	-11.0%	-39.9%	-42.4%
Relative	-8.3%	-29.3%	-40.2%
12M (H/L)		18.35/7.40	
3M Average Volume (th):		27.61	

### Shareholder Data

No. of Ord shares (mn):	26
Total no. of shares (mn):	26
Mkt Cap Ord (Eu mn):	200
Total Mkt Cap (Eu mn):	200
Mkt Float - Ord (Eu mn):	96
Mkt Float (in %):	47.9%
Main Shareholder:	
Eigenfin Srl + M. Eigenmann	52.1%

### Balance Sheet Data

Book Value (Eu mn):	148
BVPS (Eu):	5.77
P/BV:	1.4
Net Financial Position (Eu mn):	-26
Enterprise Value (Eu mn):	227

■ **1Q results: turning point on margin trajectory.** Last Friday, Fine Foods reported an unexpected turning point on margin trends (1Q: 8%, we were expecting a 5% margin in line with 4Q) which we believe should enhance visibility on current FY expectations (although at this stage we would not expect major changes in consensus) and might be well received by the market. This resulted from the actions implemented by management, such as charging increased raw material and packaging costs to clients and reducing production downtime due to stock management policies. In addition, we flag up a stronger top line (+3% vs. our exp.) mainly thanks to a greater contribution from the Cosmetics BU (18% of the total), although trends were pretty similar to 4Q: the Pharma BU (23% of the total) confirmed healthy double-digit growth (1Q: +19%, 4Q: +21%), while the Food BU (now 58%) saw a -23% decline similar to the one seen in 4Q (-21% YoY). On the negative side, we would highlight bottom line and NWC trends. The bottom line turned negative due an adverse change (at EBT level) in the parent Company's equity securities business (€-2.4mn change in FV at March 2022 vs +€1.4mn at March 2021), while net debt doubled to €33mn (from €15.7mn at YE21) due to the increase in NWC (€15.6mn increase, due to higher inventories as part of supply chain crisis management, and trade receivables due to a higher portion of clients with longer payment terms) and CapEx (€4.0mn).

■ **Slightly more positive FY22 outlook, mainly thanks to timely and effective actions.** The company expects an improvement in the Food BU from 1Q22, despite the Ukraine conflict, and positive outlooks for the Pharma BU (strong recovery from the Covid crisis) and the Cosmetics BU (integration of Pharmatek and Euro Cosmetics), both unaffected by the geopolitical situation. Policies for targeted stock increases have been successfully implemented to cope with the uncertainties of the raw material and packaging supply chain, while rising energy costs were addressed through the installation of two new photovoltaic systems. Transfers of material and energy price increases to customers have boosted margins. Management is satisfied with its risk mitigation actions, which started to have an impact in 1Q, and is ready to implement further actions if the international and domestic economic landscape requires

■ **Updated estimates.** We confirm our FY22-24 top line and margin estimates, while capturing higher D&A in FY22 (driving a 20% EPS cut) and NWC absorption (net debt now €26m by YE22, previous forecast €10mn), both in 1Q.

■ **OUTPERFORM confirmed; new target €15.0 (from €17.5).** Despite short-term headwinds for the whole CDMO industry, the unexpected turning point on margins in 1Q enhances visibility on current FY expectations, while the medium-term outlook remains extremely positive for Fine Foods: this prompts us to confirm our positive rating but reduce our DCF-based TP to €15.0 (from €17.5) to capture a +50bp increase in WACC (to 7.8%) and higher net debt at YE22. FF is well placed to outperform peers, having largely outgrown its core end-markets in the last decade, and enjoys solid operating trends by leveraging its critical mass as the largest Italian CDMO, highly visible customer demand (resulting in enduring relations and increasing share of wallet), and the additional capacity secured through investments, as well as the ability to seize further M&A opportunities for quality assets in adjacent markets or to act as a natural aggregator.

Key Figures & Ratios	2020A	2021A	2022E	2023E	2024E
Sales (Eu mn)	172	193	207	232	257
EBITDA Adj (Eu mn)	22	21	21	30	35
Net Profit Adj (Eu mn)	9	10	4	12	15
EPS New Adj (Eu)	0.398	0.398	0.175	0.462	0.575
EPS Old Adj (Eu)	0.398	0.398	0.220	0.462	0.575
DPS (Eu)	0.141	0.160	0.070	0.185	0.230
EV/EBITDA Adj	9.6	17.8	11.0	6.8	5.7
EV/EBIT Adj	20.0	nm	34.4	13.5	10.4
P/E Adj	19.7	19.7	44.8	17.0	13.6
Div. Yield	1.8%	2.0%	0.9%	2.4%	2.9%
Net Debt/EBITDA Adj	-1.9	0.7	1.3	0.2	0.0

**FINE FOODS – Key Figures**

<b>Profit &amp; Loss (Eu mn)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
Sales	160	172	193	207	232	257
EBITDA	17	21	20	21	30	35
EBIT	8	9	5	7	15	19
Financial Income (charges)	-0	-0	-1	-1	-0	-0
Associates & Others	0	0	0	0	0	0
Pre-tax Profit	0	17	-5	6	15	19
Taxes	-3	-3	3	-1	-3	-4
Tax rate		19.9%		20.0%	21.5%	22.0%
Minorities & Discontinued Operations	0	0	0	0	0	0
Net Profit	-3	13	-1	4	12	15
EBITDA Adj	20	22	21	21	30	35
EBIT Adj	11	11	8	7	15	19
Net Profit Adj	12	9	10	4	12	15
<b>Per Share Data (Eu)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
Total Shares Outstanding (mn) - Average	23	24	26	26	26	26
Total Shares Outstanding (mn) - Year End	24	24	26	26	26	26
EPS f.d	-0.119	0.570	-0.056	0.175	0.462	0.575
EPS Adj f.d	0.506	0.398	0.398	0.175	0.462	0.575
BVPS f.d	5.571	5.982	5.760	5.775	6.167	6.557
Dividend per Share ORD	0.120	0.141	0.160	0.070	0.185	0.230
Dividend per Share SAV	0.000	0.000	0.000	0.000	0.000	0.000
Dividend Payout Ratio (%)						
<b>Cash Flow (Eu mn)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
Gross Cash Flow	9	27	-1	19	27	30
Change in NWC	1	9	-14	-14	6	-4
Capital Expenditure	-20	-16	-17	-11	-12	-13
Other Cash Items	-10	1	19	0	0	0
Free Cash Flow (FCF)	-10	20	-31	-6	21	13
Acquisitions, Divestments & Other Items	0	0	-42	0	0	0
Dividends	-2	-3	-3	-4	-2	-5
Equity Financing/Buy-back	0	0	0	0	0	0
Change in Net Financial Position	-22	18	-58	-11	20	8
<b>Balance Sheet (Eu mn)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
Total Fixed Assets	93	95	144	125	122	119
Net Working Capital	16	4	39	53	47	51
Long term Liabilities	-2	-1	-4	-4	-4	-4
Net Capital Employed	106	98	179	174	164	166
Net Cash (Debt)	24	43	-16	-26	-7	1
Group Equity	131	141	147	148	158	168
Minorities	0	0	0	0	0	0
Net Equity	131	141	147	148	158	168
<b>Enterprise Value (Eu mn)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
Average Mkt Cap	242	256	361	200	200	200
Adjustments (Associate & Minorities)	0	0	0	0	0	0
Net Cash (Debt)	24	43	-16	-26	-7	1
Enterprise Value	217	213	377	227	207	199
<b>Ratios (%)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
EBITDA Adj Margin	12.7%	13.0%	11.0%	10.0%	13.0%	13.5%
EBIT Adj Margin	6.8%	6.2%	4.0%	3.2%	6.6%	7.5%
Gearing - Debt/Equity	-18.7%	-30.3%	10.6%	17.8%	4.3%	-0.8%
Interest Cover on EBIT	16.8	23.0	6.6	6.6	44.0	54.9
Net Debt/EBITDA Adj	-1.2	-1.9	0.7	1.3	0.2	0.0
ROACE*	8.2%	9.2%	3.6%	3.7%	9.1%	11.6%
ROE*	8.8%	6.9%	7.1%	3.0%	7.7%	9.0%
EV/CE	2.2	2.1	2.7	1.3	1.2	1.2
EV/Sales	1.4	1.2	2.0	1.1	0.9	0.8
EV/EBITDA Adj	10.7	9.6	17.8	11.0	6.8	5.7
EV/EBIT Adj	19.9	20.0	nm	34.4	13.5	10.4
Free Cash Flow Yield	-5.1%	10.1%	-15.7%	-3.2%	10.6%	6.4%
<b>Growth Rates (%)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
Sales	14.6%	7.7%	12.0%	7.4%	12.3%	10.8%
EBITDA Adj	8.6%	9.9%	-5.0%	-2.4%	46.5%	14.5%
EBIT Adj	7.2%	-2.5%	-27.2%	-14.9%	133.3%	24.8%
Net Profit Adj	nm	nm	nm	nm	163.8%	24.6%
EPS Adj	36.6%	-21.2%	0.0%	-56.0%	163.8%	24.6%
DPS	20.4%	16.8%	13.7%	-56.2%	163.8%	24.6%

\*Excluding extraordinary items Source: Intermonte SIM estimates

## Fine Foods in Brief


### Company description

Fine Foods (FF) is the largest independent Italian CDMO of solid oral forms for the nutraceutical and pharmaceutical industries and is also active in the cosmetics, biocides and medical devices industries with the acquisition of Pharmatek (Jan'21) and Euro Cosmetics (Oct'21). Founded in 1984, FF has been pursuing quality and innovation to serve its primary objective. With an 11% top line CAGR over the last decade, FF is a growing and future-oriented company. In July '21, less than 3 years after listing on the AIM segment, FF shares were admitted to the STAR segment of Borsa Italia.

### Strengths/Opportunities


- Exposure to secular trends (life expectancy, well-being awareness) of steadily growing and non-cyclical segments
- High customer loyalty and significant entry/exit barriers
- Increasing outsourcing to CDMOs in pharma segment
- Right scale to play consolidation in Italy
- Diversification across pharma, food, and cosmetic/biocides sector with cross-selling opportunities and cross-functional on R&D
- High employee engagement (best-in-class retention rate)

### European Nutraceutical Market Value (Eu bn, 3Y CAGR %)




Source: Euromonitor International

### European Cosmetic and Biocide Market (Eu bn, 3Y CAGR %)



Source: Euromonitor International

### Fine Foods – Net Revenue Trend (2015-2024E)



Source: Company Data (A), Intermonte Estimates (E)

### Management

**Chairman and CEO:** M. Eigenmann  
**CEO:** Giorgio Ferraris  
**CFO:** Pietro Bassani  
**IR:** Carlo Larghi

**Next BoD renewal:** Spring, 2023

**BoD independent members:** 3/7

**BoD women:** 3/7


### Shareholders

Marco Eigenmann	52.1%
Treasury Shares	5.4%
Market	42.5%
<b>Free float (ord. shares)</b>	<b>53.5%</b>

### Weaknesses/Threats


- Short-term visibility on production volumes (orders submitted by clients on quarterly basis)
- Limited customer power due to high concentration (top 5 clients c. 77% of FF sales in 2020)
- No patent protection
- Changes to the regulatory framework
- Potential shifts in consumer behaviour patterns and needs

### European Pharma Production (left) and EU CDMO Market Value (right)




Source: FY21 Company Presentation (Euromonitor International, Prometeia)

### Fine Foods – High Customer Loyalty



Source: FY21 Company Presentation

### Fine Foods – EBITDA and Margin trend (2015-2024E)



Source: Company Data (A), Intermonte Estimates (E)

## 1Q22 Results

Last Friday, Fine Foods reported an unexpected turning point on margin trends (1Q: 8%, we were expecting a 5% margin in line with 4Q) which we believe should enhance visibility on current FY expectations (although at this stage we would not expect major changes in consensus) and might be well received by the market. This resulted from the actions implemented by management, such as charging increased raw material and packaging costs to clients and reducing production downtime through stock management policies.

In addition, we flag up a stronger top line (+3% vs. our exp.) mainly thanks to a greater contribution from the Cosmetics BU (18% of the total), although trends were pretty similar to 4Q: the Pharma BU (23% of the total) confirmed healthy double-digit growth (1Q: +19%, 4Q: +21%), while the Food BU (now 58%) saw a -23% decline similar to the one seen in 4Q (-21% YoY). On the negative side, we would highlight bottom line and NWC trends.

The bottom line turned negative due an adverse change (at EBT level) in the parent Company's equity securities business (€-2.4mn change in FV at March 2022 vs +€1.4mn at March 2021), while net debt doubled to €33mn (from €15.7mn at YE21) due to the increase in NWC (€15.6mn increase, due to higher inventories as part of supply chain crisis management, and trade receivables due to a higher portion of clients with longer payment terms) and CapEx (€4.0mn).

### Fine Foods – 1Q22 Results: P&L\*

P&L (Eu mn)	2020A	1Q21A	2Q21A	1H21A	3Q21A	9M21A	4Q21A	2021A	1Q22A	1Q22E	A/E
<b>Food</b>	<b>132.0</b>	<b>38.3</b>	<b>35.0</b>	<b>73.3</b>	<b>33.1</b>	<b>106.4</b>	<b>31.7</b>	<b>138.1</b>	<b>29.5</b>	<b>31.0</b>	
YoY growth	10.7%			35.4%	-11.7%	16.1%	-21.4%	4.7%	-22.9%	-19.0%	
on net sales	76.8%	74.6%	74.0%	74.3%	74.0%	74.2%	64.3%	71.7%	58.2%	62.9%	
<b>Pharma</b>	<b>40.0</b>	<b>10.0</b>	<b>9.3</b>	<b>19.3</b>	<b>8.9</b>	<b>28.2</b>	<b>10.1</b>	<b>38.3</b>	<b>11.9</b>	<b>12.3</b>	
YoY growth	-1.2%			-9.0%	-9.2%	-9.1%	11.8%	-4.4%	18.6%	23.2%	
on net sales	23.3%	19.5%	19.7%	19.6%	19.8%	19.7%	20.5%	19.9%	23.4%	25.0%	
<b>Cosmetics &amp; Biocides</b>				<b>6.0</b>	<b>2.8</b>	<b>8.8</b>	<b>7.5</b>	<b>16.3</b>	<b>9.4</b>	<b>6.0</b>	
on net sales				6.1%	6.2%	6.1%	15.2%	8.5%	18.4%	12.2%	
<b>Net revenues</b>	<b>172.0</b>	<b>51.3</b>	<b>47.3</b>	<b>98.6</b>	<b>44.8</b>	<b>143.4</b>	<b>49.3</b>	<b>192.6</b>	<b>50.8</b>	<b>49.3</b>	<b>3%</b>
YoY growth	7.7%	0.0%	0.0%	30.7%	-5.3%	16.9%	-0.1%	12.0%	-1.1%	-3.9%	
Other income	5.0	0.1	1.1	1.2	0.5	1.7	0.9	2.6	0.2	0.2	
<b>Value of production</b>	<b>177.0</b>	<b>51.4</b>	<b>48.4</b>	<b>99.8</b>	<b>45.3</b>	<b>145.1</b>	<b>50.3</b>	<b>195.2</b>	<b>50.9</b>	<b>49.6</b>	<b>3%</b>
<b>Raw materials</b>	<b>(109.0)</b>	<b>(31.1)</b>	<b>(25.5)</b>	<b>(56.6)</b>	<b>(30.4)</b>	<b>(87.1)</b>	<b>(31.6)</b>	<b>(118.7)</b>	<b>(30.9)</b>	<b>(31.0)</b>	
on net sales	-63.4%	-60.6%	-54.0%	-57.4%	-68.0%	-60.7%	-64.1%	-61.6%	-60.9%	-62.8%	
<b>Personnel</b>	<b>(31.0)</b>	<b>(8.9)</b>	<b>(0.2)</b>	<b>(9.2)</b>	<b>(15.9)</b>	<b>(25.1)</b>	<b>(9.7)</b>	<b>(34.8)</b>	<b>(9.4)</b>	<b>(9.6)</b>	
on net sales	-18.0%	-17.4%	-0.5%	-9.3%	-35.6%	-17.5%	-19.7%	-18.1%	-18.5%	-19.5%	
<b>Cost of services</b>	<b>(15.0)</b>	<b>(4.3)</b>	<b>(13.2)</b>	<b>(17.4)</b>	<b>3.4</b>	<b>(14.0)</b>	<b>(6.8)</b>	<b>(20.8)</b>	<b>(6.3)</b>	<b>(6.4)</b>	
on net sales	-8.7%	-8.3%	-27.9%	-17.7%	7.6%	-9.8%	-13.8%	-10.8%	-12.3%	-13.0%	
<b>Other costs</b>	<b>(0.9)</b>	<b>(0.4)</b>	<b>(3.3)</b>	<b>(3.7)</b>	<b>2.8</b>	<b>(0.9)</b>	<b>(0.4)</b>	<b>(1.3)</b>	<b>(0.4)</b>	<b>(0.1)</b>	
on net sales	-0.5%	-0.7%	-7.1%	-3.8%	6.3%	-0.6%	-0.8%	-0.7%	-0.8%	-0.2%	
<b>Total Opex</b>	<b>(155.9)</b>	<b>(44.7)</b>	<b>(42.3)</b>	<b>(86.9)</b>	<b>(40.1)</b>	<b>(127.1)</b>	<b>(48.5)</b>	<b>(175.6)</b>	<b>(46.9)</b>	<b>(47.1)</b>	
<b>EBITDA</b>	<b>21.1</b>	<b>6.8</b>	<b>6.1</b>	<b>12.9</b>	<b>5.1</b>	<b>18.0</b>	<b>1.6</b>	<b>19.6</b>	<b>4.0</b>	<b>2.5</b>	<b>61%</b>
YoY growth	20.6%			56.0%	-28.4%	16.8%	-71.2%	-6.9%	-41.4%	-63.5%	
as % of net sales	12.3%	13.2%	12.9%	13.0%	11.4%	12.5%	3.3%	10.2%	7.8%	5.0%	
<b>Adj. EBITDA</b>	<b>22.3</b>	<b>6.8</b>	<b>6.4</b>	<b>13.1</b>	<b>5.7</b>	<b>18.8</b>	<b>2.4</b>	<b>21.2</b>	<b>4.0</b>	<b>2.5</b>	<b>61%</b>
YoY growth	9.9%			46.9%	-22.8%	15.4%	-60.0%	-5.0%	-41.4%	-63.5%	
as % of net sales	13.0%	13.2%	13.5%	13.3%	12.7%	13.1%	4.8%	11.0%	7.8%	5.0%	
<b>D&amp;A</b>	<b>(11.6)</b>	<b>(3.1)</b>	<b>(3.3)</b>	<b>(6.4)</b>	<b>(3.8)</b>	<b>(10.2)</b>	<b>(4.4)</b>	<b>(14.6)</b>	<b>(3.6)</b>	<b>(3.1)</b>	
<b>EBIT</b>	<b>9.4</b>	<b>3.7</b>	<b>2.8</b>	<b>6.5</b>	<b>1.3</b>	<b>7.8</b>	<b>(2.7)</b>	<b>5.1</b>	<b>0.4</b>	<b>(0.7)</b>	
<b>Adj. EBIT</b>	<b>10.7</b>	<b>3.7</b>	<b>3.1</b>	<b>6.7</b>	<b>1.9</b>	<b>8.6</b>	<b>(0.9)</b>	<b>7.8</b>	<b>0.4</b>	<b>(0.7)</b>	
as % of net sales	6.2%	7.1%	6.5%	6.8%	4.3%	6.0%	-1.8%	4.0%	0.8%	-1.4%	
<b>Pretax</b>	<b>16.7</b>	<b>3.1</b>	<b>(7.2)</b>	<b>(4.1)</b>	<b>1.3</b>	<b>(2.7)</b>	<b>(1.9)</b>	<b>(4.6)</b>	<b>(2.3)</b>	<b>(0.8)</b>	
Taxes	(3.3)	(1.3)	(1.1)	(2.4)	1.7	(0.7)	3.9	3.2	(0.2)	0.2	
tax rate	-20%	0%	0%	59%	n.m.	n.m.	n.m.	n.m.	n.m.	-20%	
<b>Net income</b>	<b>13.4</b>	<b>1.8</b>	<b>(8.3)</b>	<b>(6.5)</b>	<b>3.0</b>	<b>(3.4)</b>	<b>2.0</b>	<b>(1.4)</b>	<b>(2.5)</b>	<b>(0.6)</b>	
<b>Adj. Net Income</b>	<b>9.3</b>	<b>3.1</b>	<b>3.3</b>	<b>6.5</b>	<b>3.0</b>	<b>9.5</b>	<b>0.7</b>	<b>10.2</b>	<b>(2.5)</b>	<b>(0.6)</b>	

Source: Company Data (A), Intermonte Estimates (E)

\* We remind investors that 1Q22 was the first time that Fine Foods published its first-quarter results since the company listing on the STAR segment in July 2021. Therefore, many details on historical figures for 1Q21 and 2Q21 are missing.

**Fine Foods – FY21 Results: FCF & Net Debt evolution and Reclassified Balance Sheet\***

<b>FCF (Eu mn)</b>	<b>2020A</b>	<b>1Q21A</b>	<b>1H21A</b>	<b>9M21A</b>	<b>2021A</b>	<b>1Q22A</b>	<b>1Q22E</b>	<b>A-E</b>
Net Profit	13.4	1.8	(6.5)	(3.4)	(1.4)	(2.5)	(0.6)	(1.8)
D&A	11.6	3.1	6.4	10.2	14.6	3.6	3.2	0.4
Delta Op. WKC	9.4	(16.8)	(13.1)	(26.5)	(14.4)	(15.6)	(10.0)	(5.6)
Chg. in other funds	1.8	2.4	(5.0)	11.1	(13.7)	3.9	-	3.9
<b>FCF before Capex</b>	<b>36.2</b>	<b>(9.6)</b>	<b>(18.2)</b>	<b>(8.6)</b>	<b>(15.0)</b>	<b>(10.6)</b>	<b>(7.5)</b>	<b>(3.1)</b>
Capex	(16.0)	(2.0)	(5.8)	(7.6)	(16.5)	(4.0)	(1.5)	(2.5)
<b>Equity FCF</b>	<b>20.2</b>	<b>(11.5)</b>	<b>(24.0)</b>	<b>(16.2)</b>	<b>(31.5)</b>	<b>(14.6)</b>	<b>(9.0)</b>	<b>(5.6)</b>
Acquisitions	-	(9.6)	(17.2)	(17.2)	(42.4)	-	-	-
Disposals	-	-	-	-	-	-	-	-
Dividends	(2.7)	-	(3.2)	(3.2)	(3.2)	-	-	-
Share Buy-back	(4.0)	(0.8)	(2.4)	(6.2)	(7.5)	(0.1)	-	(0.1)
Rights Issue/ ipo	-	-	-	-	-	-	-	-
Other	5.0	-	24.7	10.7	26.1	(2.7)	-	(2.7)
<b>Change in NFP</b>	<b>18.4</b>	<b>(22.0)</b>	<b>(22.1)</b>	<b>(32.1)</b>	<b>(58.5)</b>	<b>(17.3)</b>	<b>(9.0)</b>	<b>(8.4)</b>
<b>Opening NFP</b>	<b>24.4</b>	<b>-</b>	<b>42.8</b>	<b>42.8</b>	<b>42.8</b>	<b>(15.7)</b>	<b>(15.7)</b>	<b>-</b>
Change in NFP	18.4	(22.0)	(22.1)	(32.1)	(58.5)	(17.3)	(9.0)	(8.4)
<b>Ending NFP(Debt)</b>	<b>42.8</b>	<b>20.8</b>	<b>20.7</b>	<b>10.6</b>	<b>(15.7)</b>	<b>(33.0)</b>	<b>(24.7)</b>	<b>(8.4)</b>

<b>Balance Sheet (Eu mn)</b>	<b>2020A</b>	<b>1Q21A</b>	<b>1H21A</b>	<b>9M21A</b>	<b>2021A</b>	<b>1Q22A</b>
<b>Fixed Assets</b>	<b>95.3</b>		<b>111.5</b>	<b>110.8</b>	<b>127.8</b>	<b>128.6</b>
Inventories	19.6		26.4	27.9	35.1	37.4
Trade Receivables	12.7		24.7	25.3	29.4	42.4
Trade Payables	(22.7)		(26.5)	(23.1)	(32.5)	(32.4)
<b>Operating Working Capital</b>	<b>9.6</b>		<b>24.5</b>	<b>30.2</b>	<b>32.0</b>	<b>47.4</b>
Other curr assets	4.9		10.5	10.9	15.5	14.8
Other current liabilities	(10.0)		(11.9)	(7.1)	(8.2)	(9.1)
<b>Net Working Capital</b>	<b>4.4</b>		<b>23.0</b>	<b>34.0</b>	<b>39.2</b>	<b>53.1</b>
Provisions	(0.4)		(0.5)	(0.6)	(1.1)	(1.1)
Employees benefits	(1.1)		(1.4)	(1.4)	(3.0)	(2.9)
Others	-		-	-	-	-
<b>Net capital employed</b>	<b>98.2</b>		<b>132.6</b>	<b>142.8</b>	<b>162.9</b>	<b>177.7</b>
<b>Total equity</b>	<b>141.0</b>		<b>153.3</b>	<b>153.4</b>	<b>147.2</b>	<b>144.7</b>
<b>Net Cash (Debt)</b>	<b>42.8</b>		<b>20.8</b>	<b>10.6</b>	<b>(15.7)</b>	<b>(33.0)</b>
Cash	75.0		74.8	70.8	95.1	105.3
Gross Debt	(32.2)		(54.0)	(60.1)	(110.8)	(138.3)
<b>Total Funds</b>	<b>98.2</b>		<b>132.5</b>	<b>142.8</b>	<b>162.9</b>	<b>177.7</b>

Source: Company Data (A), Intermonte Estimates (E)

\* We remind investors that 1Q22 was the first time that Fine Foods published its first-quarter results since the company listing on the STAR segment in July 2021. Therefore, many details on historical figures for 1Q21 and 2Q21 are missing.

## Changes to Estimates

We confirm our FY22-24 top line and margin estimates, while for we capture higher D&A (driving a 20% EPS cut) and NWC absorption (net debt now at €26m by YE22, previous forecast €10mn), both witnessed in 1Q. At this stage we are not capturing the adverse change in fair value (€-2.4mn in 1Q, at EBT level) of the parent Company's equity securities business, as we believe it might unwind during the remainder of the year.

### Fine Foods – Changes to Estimates

(Eu mn)	'19A	'20A	'21A	New Estimates			Old Estimates			New vs Old		
				'22E	'23E	'24E	'22E	'23E	'24E	'22E	'23E	'24E
Food	119.2	132.0	138.1	129.9	142.8	157.1	129.9	142.8	157.1	0%	0%	0%
Pharma	40.5	40.0	38.3	44.0	50.6	55.2	44.0	50.6	55.2	0%	0%	0%
Cosmetics	0.0	0.0	16.3	32.9	38.9	45.1	32.9	38.9	45.1	0%	0%	0%
<b>Revenues</b>	<b>159.7</b>	<b>172.0</b>	<b>192.6</b>	<b>206.8</b>	<b>232.3</b>	<b>257.4</b>	<b>206.8</b>	<b>232.3</b>	<b>257.4</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>
YoY growth	14.6%	7.7%	12.0%	7.4%	12.3%	10.8%	7.4%	12.3%	10.8%			
o/w organic	14.6%	7.7%	2.6%	-1.4%	12.3%	10.8%	-1.4%	12.3%	10.8%			
EBITDA	17.5	21.1	19.6	20.7	30.3	34.6	20.7	30.3	34.6	0%	0%	0%
<b>Adj. EBITDA</b>	<b>20.3</b>	<b>22.3</b>	<b>21.2</b>	<b>20.7</b>	<b>30.3</b>	<b>34.6</b>	<b>20.7</b>	<b>30.3</b>	<b>34.6</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>
% on sales	12.7%	13.0%	11.0%	10.0%	13.0%	13.5%	10.0%	13.0%	13.5%			
D&A	(9.4)	(11.6)	(13.4)	(14.1)	(14.9)	(15.4)	(13.2)	(14.9)	(15.4)			
<b>Adj. EBIT</b>	<b>10.9</b>	<b>10.7</b>	<b>7.8</b>	<b>6.6</b>	<b>15.4</b>	<b>19.2</b>	<b>7.4</b>	<b>15.4</b>	<b>19.2</b>	<b>-11%</b>	<b>0%</b>	<b>0%</b>
% on sales	6.8%	6.2%	4.0%	3.2%	6.6%	7.5%	3.6%	6.6%	7.5%			
EBIT	8.1	9.4	5.1	6.6	15.4	19.2	7.4	15.4	19.2	-11%	0%	0%
<b>Pre taxes</b>	<b>0.1</b>	<b>16.7</b>	<b>(4.6)</b>	<b>5.6</b>	<b>15.0</b>	<b>18.9</b>	<b>7.0</b>	<b>15.0</b>	<b>18.9</b>	<b>-20%</b>	<b>0%</b>	<b>0%</b>
taxes	(2.9)	(3.3)	3.2	(1.1)	(3.2)	(4.1)	(1.4)	(3.2)	(4.1)			
tax rate	n.m.	20%	69%	20%	22%	22%	20%	22%	22%			
<b>Net Profit</b>	<b>(2.8)</b>	<b>13.4</b>	<b>(1.4)</b>	<b>4.5</b>	<b>11.8</b>	<b>14.7</b>	<b>5.6</b>	<b>11.8</b>	<b>14.7</b>	<b>-20%</b>	<b>0%</b>	<b>0%</b>
<b>Adj. Net profit</b>	<b>11.9</b>	<b>9.3</b>	<b>10.2</b>	<b>4.5</b>	<b>11.8</b>	<b>14.7</b>	<b>5.6</b>	<b>11.8</b>	<b>14.7</b>	<b>-20%</b>	<b>0%</b>	<b>0%</b>
Adj. EPS (€/share)	0.51	0.40	0.40	0.18	0.46	0.58	0.22	0.46	0.58	-20%	0%	0%
<b>DPS (€/share)</b>	<b>0.12</b>	<b>0.14</b>	<b>0.16</b>	<b>0.07</b>	<b>0.18</b>	<b>0.23</b>	<b>0.09</b>	<b>0.18</b>	<b>0.23</b>	<b>-20%</b>	<b>0%</b>	<b>0%</b>
% payout on Adj. EPS	24%	35%	40%	40%	40%	40%	40%	40%	40%			
<b>Adj. EBITDA</b>	<b>20.3</b>	<b>22.3</b>	<b>21.2</b>	<b>20.7</b>	<b>30.3</b>	<b>34.6</b>	<b>20.7</b>	<b>30.3</b>	<b>34.6</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>
CapEx	(20.1)	(16.0)	(16.5)	(11.4)	(11.6)	(12.9)	(11.4)	(11.6)	(12.9)	0%	0%	0%
% on sales	12.6%	9.3%	8.6%	5.5%	5.0%	5.0%	5.5%	5.0%	5.0%			
<b>EBITDA-Capex</b>	<b>0.2</b>	<b>6.3</b>	<b>4.7</b>	<b>9.3</b>	<b>18.6</b>	<b>21.8</b>	<b>9.3</b>	<b>18.6</b>	<b>21.8</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>
% of Adj. EBITDA	1%	28%	22%	45%	62%	63%	45%	62%	63%			
NWC change	0.5	9.4	(14.4)	(13.7)	6.3	(4.4)	3.1	(4.6)	(3.8)			
<b>Op. FCF</b>	<b>0.7</b>	<b>15.7</b>	<b>(9.7)</b>	<b>(4.4)</b>	<b>24.9</b>	<b>17.3</b>	<b>12.4</b>	<b>14.0</b>	<b>18.0</b>	<b>n.m.</b>	<b>78%</b>	<b>-3%</b>
% of Adj. EBITDA	3%	70%	-46%	-21%	82%	50%	60%	46%	52%			
<b>Equity FCF</b>	<b>(10.2)</b>	<b>20.2</b>	<b>(31.5)</b>	<b>(6.5)</b>	<b>21.3</b>	<b>12.8</b>	<b>10.6</b>	<b>10.4</b>	<b>13.5</b>	<b>n.m.</b>	<b>105%</b>	<b>-5%</b>
% of Adj. EBITDA	-50%	91%	-149%	-31%	70%	37%	51%	34%	39%			
<b>NFP/ (Debt)</b>	<b>24.4</b>	<b>42.8</b>	<b>(15.7)</b>	<b>(26.3)</b>	<b>(6.7)</b>	<b>1.4</b>	<b>(9.2)</b>	<b>(1.0)</b>	<b>7.7</b>	<b>n.m.</b>	<b>n.m.</b>	<b>n.m.</b>
/Adj. EBITDA(x)	1.2x	1.9x	-0.7x	-1.3x	-0.2x	0.0x	-0.4x	0.0x	0.2x			

Source: Company Data (A), Intermonte Estimates (E)

#### Fine Foods – P&L

(Eu mn)	'15A	'16A	'17A	'18A	'19A	'20A	'21A	'22E	'23E	'24E
<b>Total Revenues</b>	<b>102</b>	<b>113</b>	<b>120</b>	<b>139</b>	<b>160</b>	<b>172</b>	<b>193</b>	<b>207</b>	<b>232</b>	<b>257</b>
Total OpEx	(89)	(98)	(104)	(121)	(142)	(151)	(173)	(186)	(202)	(223)
<b>EBITDA</b>	<b>13</b>	<b>15</b>	<b>16</b>	<b>19</b>	<b>17</b>	<b>21</b>	<b>20</b>	<b>21</b>	<b>30</b>	<b>35</b>
% EBITDA Margin	0	0	0	0	0	0	0	0	0	0
D&A and writedown	(5)	(6)	(7)	(8)	(9)	(12)	(15)	(14)	(15)	(15)
<b>EBIT</b>	<b>8</b>	<b>9</b>	<b>9</b>	<b>10</b>	<b>8</b>	<b>9</b>	<b>5</b>	<b>7</b>	<b>15</b>	<b>19</b>
% EBIT Margin	0	0	0	0	0	0	0	0	0	0
Net Financial Charges	(0)	(0)	(0)	0	(0)	(0)	(1)	(1)	(0)	(0)
Other Charges and Income	0	0	0	0	0	0	0	0	0	0
<b>Net Operating Margin</b>	<b>8</b>	<b>9</b>	<b>9</b>	<b>10</b>	<b>0</b>	<b>17</b>	<b>(5)</b>	<b>6</b>	<b>15</b>	<b>19</b>
Taxes	(3)	(3)	(2)	(2)	(3)	(3)	3	(1)	(3)	(4)
Tax Rate %	(0)	(0)	(0)	(0)	n.m.	(0)	n.m	(0)	(0)	(0)
<b>Net Income</b>	<b>5</b>	<b>6</b>	<b>6</b>	<b>9</b>	<b>(3)</b>	<b>13</b>	<b>(1)</b>	<b>4</b>	<b>12</b>	<b>15</b>
<b>Adj. Net Income</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>9</b>	<b>12</b>	<b>9</b>	<b>10</b>	<b>4</b>	<b>12</b>	<b>15</b>

#### Fine Foods – BS

(Eu mn)	'15A	'16A	'17A	'18A	'19A	'20A	'21A	'22E	'23E	'24E
Intangible Assets	1	1	1	4	3	2	25	25	25	25
Tangible Assets	39	42	57	79	89	93	103	100	97	94
Financial Assets	0	0	0	0	0	0	0	0	0	0
<b>Total Fixed Assets</b>	<b>40</b>	<b>43</b>	<b>59</b>	<b>82</b>	<b>93</b>	<b>95</b>	<b>128</b>	<b>125</b>	<b>122</b>	<b>119</b>
NWC	10	10	2	19	16	4	39	53	47	51
<b>Gross inv. capital</b>	<b>51</b>	<b>53</b>	<b>61</b>	<b>101</b>	<b>108</b>	<b>100</b>	<b>167</b>	<b>178</b>	<b>168</b>	<b>170</b>
other funds	(1)	(1)	(1)	(8)	(2)	(1)	(4)	(4)	(4)	(4)
<b>Net invested capital</b>	<b>49</b>	<b>52</b>	<b>59</b>	<b>93</b>	<b>106</b>	<b>98</b>	<b>163</b>	<b>174</b>	<b>164</b>	<b>166</b>
Group Equity	31	33	39	140	131	141	147	148	158	168
Minority interests	0	0	0	0	0	0	0	0	0	0
<b>Net Cash (Debt)</b>	<b>(18)</b>	<b>(19)</b>	<b>(20)</b>	<b>47</b>	<b>24</b>	<b>43</b>	<b>(16)</b>	<b>(26)</b>	<b>(7)</b>	<b>1</b>
<b>Total cover</b>	<b>49</b>	<b>52</b>	<b>59</b>	<b>93</b>	<b>106</b>	<b>98</b>	<b>163</b>	<b>174</b>	<b>164</b>	<b>166</b>

#### Fine Foods – FCF

(Eu mn)	'15A	'16A	'17A	'18A	'19A	'20A	'21A	'22E	'23E	'24E
<b>Net Profit</b>	<b>5</b>	<b>6</b>	<b>6</b>	<b>9</b>	<b>(3)</b>	<b>13</b>	<b>(1)</b>	<b>4</b>	<b>12</b>	<b>15</b>
D&A	5	6	7	8	9	12	15	14	15	15
Delta Op. WKC	(5)	(1)	5	(11)	1	9	(14)	(14)	6	(4)
Change in funds/other	(1)	1	4	(6)	3	2	(14)	0	0	0
<b>FCF before Capex</b>	<b>4</b>	<b>12</b>	<b>21</b>	<b>0</b>	<b>10</b>	<b>36</b>	<b>(15)</b>	<b>5</b>	<b>33</b>	<b>26</b>
Capex (Fixed & Intangible Assets)	(8)	(10)	(22)	(32)	(20)	(16)	(17)	(11)	(12)	(13)
<b>Equity FCF</b>	<b>(3)</b>	<b>2</b>	<b>(1)</b>	<b>(31)</b>	<b>(10)</b>	<b>20</b>	<b>(31)</b>	<b>(6)</b>	<b>21</b>	<b>13</b>
Acquisitions	0	0	0	0	0	0	(42)	0	0	0
Disposals	0	0	0	0	0	0	0	0	0	0
Dividends	0	(5)	0	0	(2)	(3)	(3)	(4)	(2)	(5)
Share Buy-back	0	0	0	0	(5)	(4)	(8)	0	0	0
Rights Issue/ ipo	0	0	0	100	0	0	0	0	0	0
Other	(0)	2	(0)	(1)	(5)	5	26	0	0	0
<b>Change in NFP</b>	<b>(4)</b>	<b>(1)</b>	<b>(1)</b>	<b>67</b>	<b>(22)</b>	<b>18</b>	<b>(58)</b>	<b>(11)</b>	<b>20</b>	<b>8</b>
Opening Net Cash (Debt)	(14)	(18)	(19)	(20)	47	24	43	(16)	(26)	(7)
<b>Ending Net Cash (Debt)</b>	<b>(18)</b>	<b>(19)</b>	<b>(20)</b>	<b>47</b>	<b>24</b>	<b>43</b>	<b>(16)</b>	<b>(26)</b>	<b>(7)</b>	<b>1</b>



## DCF Valuation

Rolling our DCF valuation over by one year and reflecting a 50bp increase in our WACC (now 7.8%, due to a higher risk-free rate moving from 2.0% to 2.5%, while g remains at 2.5%) and a higher YE22 net debt (now €26m vs. our previous forecast of €10mn), we are lowering our DCF-based TP to €15.0 (from €17.5). At TP, which offers c.90% upside to the current price, the stock would trade at 11x EV/EBITDA'24E (currently 6x) in line with average of selected peers.

### Fine Foods – DCF Model

(Eu mn)	22E	23E	24E	25E	26E	27E	28E	29E	30E	31E	32E	TV
<b>Net Revenues</b>	<b>206.8</b>	<b>232.3</b>	<b>257.4</b>	<b>281.5</b>	<b>304.7</b>	<b>328.8</b>	<b>354.5</b>	<b>382.6</b>	<b>410.9</b>	<b>437.2</b>	<b>465.9</b>	<b>477.5</b>
<i>YoY growth</i>	7.4%	12.3%	10.8%	9.3%	8.2%	7.9%	7.8%	7.9%	7.4%	6.4%	6.6%	2.5%
<b>EBITDA</b>	<b>20.7</b>	<b>30.3</b>	<b>34.6</b>	<b>39.0</b>	<b>43.2</b>	<b>46.7</b>	<b>50.4</b>	<b>54.4</b>	<b>58.5</b>	<b>62.3</b>	<b>66.5</b>	<b>66.9</b>
% margin	10.0%	13.0%	13.5%	13.9%	14.2%	14.2%	14.2%	14.2%	14.2%	14.3%	14.3%	14.0%
D&A	(14.1)	(14.9)	(15.4)	(16.9)	(18.3)	(19.7)	(21.3)	(23.0)	(24.7)	(26.2)	(28.0)	(28.7)
as % of sales	6.8%	6.4%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	5.5%
<b>EBIT</b>	<b>6.6</b>	<b>15.4</b>	<b>19.2</b>	<b>22.1</b>	<b>25.0</b>	<b>27.0</b>	<b>29.1</b>	<b>31.5</b>	<b>33.9</b>	<b>36.1</b>	<b>38.5</b>	<b>38.2</b>
% margin	3.2%	6.6%	7.5%	7.9%	8.2%	8.2%	8.2%	8.2%	8.2%	8.3%	8.3%	8.0%
Taxes	(1.6)	(3.7)	(4.6)	(5.3)	(6.0)	(6.5)	(7.0)	(7.6)	(8.1)	(8.7)	(9.3)	(9.2)
<i>tax rate</i>	24.0%	24.0%	24.0%	24.0%	24.0%	24.0%	24.0%	24.0%	24.0%	24.0%	24.0%	24.0%
Change in WC	(13.7)	6.3	(4.4)	(4.3)	(4.1)	(4.1)	(4.4)	(4.8)	(4.9)	(4.5)	(4.9)	-
Capex	(11.4)	(11.6)	(12.9)	(14.1)	(15.2)	(16.4)	(17.7)	(19.1)	(20.5)	(21.9)	(23.3)	(28.7)
as % of sales	5.5%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.5%
<b>Unlevered FCF</b>	<b>(6.0)</b>	<b>21.2</b>	<b>12.7</b>	<b>15.3</b>	<b>17.9</b>	<b>19.6</b>	<b>21.3</b>	<b>22.9</b>	<b>25.0</b>	<b>27.3</b>	<b>29.0</b>	<b>29.0</b>
TV												549.4
year		1.0	2.0	3.0	4.0	5.0	6.0	7.0	8.0	9.0	10.0	10.0
Discounted WACC		0.9	0.9	0.8	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.5
<b>Discounted Free cash flow</b>		<b>19.7</b>	<b>11.0</b>	<b>12.2</b>	<b>13.2</b>	<b>13.5</b>	<b>13.6</b>	<b>13.6</b>	<b>13.7</b>	<b>13.9</b>	<b>13.7</b>	<b>259.6</b>

Discounted FCF '23E-31E	138.1
Terminal value	259.6
<b>Total EV</b>	<b>397.7</b>
NFP/(Debt) at YE22	(26.3)
Minorities	0.0
own shares	10.9
<b>Total EQUITY (Eu mn)</b>	<b>382.4</b>
NOSH (mn)	25.6
<b>Fair value (Eu/share)</b>	<b>15.0</b>

current price (Eu/share)	7.8
<i>upside vs current price</i>	91%

### Fine Foods - TP Sensitivity to WACC (%) and g (%)

	g										
	2.0%	2.1%	2.2%	2.3%	2.4%	2.5%	2.6%	2.7%	2.8%	2.9%	3.0%
<b>6.8%</b>	16.0	16.2	16.5	16.7	17.0	<b>17.3</b>	17.6	18.0	18.3	18.7	19.1
<b>7.0%</b>	15.5	15.7	16.0	16.2	16.5	<b>16.8</b>	17.1	17.4	17.7	18.0	18.3
<b>7.2%</b>	15.1	15.3	15.5	15.8	16.0	<b>16.3</b>	16.5	16.8	17.1	17.4	17.7
<b>7.4%</b>	14.7	14.9	15.1	15.3	15.6	<b>15.8</b>	16.0	16.3	16.5	16.8	17.1
<b>7.6%</b>	14.4	14.6	14.7	14.9	15.1	<b>15.4</b>	15.6	15.8	16.1	16.3	16.6
<b>7.8%</b>	<b>14.0</b>	<b>14.2</b>	<b>14.4</b>	<b>14.6</b>	<b>14.8</b>	<b>15.0</b>	<b>15.2</b>	<b>15.4</b>	<b>15.6</b>	<b>15.8</b>	<b>16.1</b>
<b>8.0%</b>	13.7	13.9	14.1	14.2	14.4	<b>14.6</b>	14.8	15.0	15.2	15.4	15.6
<b>8.2%</b>	13.4	13.6	13.7	13.9	14.1	<b>14.2</b>	14.4	14.6	14.8	15.0	15.2
<b>8.4%</b>	13.2	13.3	13.5	13.6	13.8	<b>13.9</b>	14.1	14.3	14.4	14.6	14.8
<b>8.6%</b>	12.9	13.0	13.2	13.3	13.5	<b>13.6</b>	13.8	13.9	14.1	14.3	14.5
<b>8.8%</b>	12.7	12.8	12.9	13.1	13.2	<b>13.3</b>	13.5	13.6	13.8	14.0	14.1

Source: Intermonte SIM



## Peer Multiples


Given the lack of a meaningful comparison provided by the peer group due to significant diversification in terms of size, vertical integration, geographical footprint, capital structure and profitability compared to Fine Foods, we do not take the peer multiples method into account in our valuation. **At current prices, Fine Foods is trading at 6.7/5.6x EV/adj. EBITDA for '23/'24, a discount of c.40% to the peer group (10-11x) and well below its historical averages.**

### Fine Foods - Peer Multiples

Company	Currency	Price	Mkt. Cap (Eu mn)	Abs. Perf. (%)			EV/Sales (x)			EV/EBITDA (x)			EV/EBIT (x)			Adj. P/E (x)			Div. Yield (%)		
				1m	6m	Ytd	'22E	'23E	'24E	'22E	'23E	'24E	'22E	'23E	'24E	'22E	'23E	'24E	'22E	'23E	'24E
FF (@mkt price, our est.)	EUR	7.84	200	-11.0%	-55.7%	-49.1%	1.0	0.9	0.7	10.1	6.7	5.6	28.2	13.1	10.0	35.7	17.0	13.6	1.1%	2.4%	2.9%
FF (@mkt price, cons.)	EUR	7.84	200	-11.0%	-55.7%	-49.1%	1.0	0.9	0.7	10.1	6.7	5.6	29.0	13.1	10.1	35.6	16.7	13.6	1.7%	2.4%	2.9%
FF (@ our TP, our est.)	EUR	15.0	446				1.9	1.7	1.5	19.0	12.7	10.8	52.8	24.9	19.5	79.5	37.8	30.4	0.6%	1.2%	1.5%
Catalent	USD	98.18	16,927	-2.7%	-23.3%	-23.3%	4.3	3.9	3.5	16.3	14.5	12.5	21.2	18.4	15.5	24.6	21.8	18.5	0.0%	0.0%	0.0%
InterCos	EUR	12.24	1,178	0.2%	-21.7%	-12.9%	1.6	1.5	1.4	11.1	9.6	8.6	17.8	14.7	12.7	24.1	20.5	17.7	1.0%	1.5%	2.0%
Labomar SpA	EUR	8.10	150	-8.4%	-34.1%	-19.0%	2.1	1.9	1.6	11.7	10.0	8.4	21.2	18.1	14.3	24.7	21.6	17.7	1.2%	1.4%	1.7%
Lonza Group AG	CHF	551.20	39,409	-16.4%	-25.2%	-27.6%	6.7	6.0	5.4	21.4	18.6	16.1	29.6	25.2	21.5	34.9	29.7	24.9	0.6%	0.6%	0.6%
Siegfried Holding AG	CHF	623.00	2,651	-18.3%	-29.4%	-30.0%	2.6	2.5	2.3	12.7	11.6	10.5	19.7	18.1	16.3	20.9	19.1	17.8	0.6%	0.6%	0.7%
Strides Pharma	INR	280.55	313	-22.7%	-44.9%	-37.3%	0.5	0.4	n.a.	3.9	2.8	n.a.	7.8	4.4	n.a.	0.3	0.1	n.a.	1.5%	1.9%	0.0%
Peer Group							2.4	2.2	2.3	12.2	10.8	10.5	20.5	18.1	15.5	24.4	21.0	17.8	0.8%	1.0%	0.6%
FF discount to peers							-57%	-60%	-67%	-17%	-39%	-47%	38%	-28%	-35%	46%	-19%	-24%			


Source: Intermonte SIM (Fine Foods), Consensus (Factset)

### Fine Foods - EV/EBITDA NTM evolution



Source: FactSet Consensus

### Fine Foods - P/E NTM evolution



Source: FactSet Consensus

DETAILS ON STOCKS RECOMMENDATION			
Stock NAME	FINE FOODS		
Current Recomm:	OUTPERFORM	Previous Recomm:	OUTPERFORM
Current Target (Eu):	15.00	Previous Target (Eu):	17.50
Current Price (Eu):	7.84	Previous Price (Eu):	13.55
Date of report:	16/05/2022	Date of last report:	31/03/2022

# DISCLAIMER (for more details go to [DISCLAIMER](#))

## IMPORTANT DISCLOSURES

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution.

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or sell securities.

This disclaimer is constantly updated on Intermonte's website [www.intermonte.it](http://www.intermonte.it) under LEGAL INFORMATION. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the [PERFORMANCE](#) web page.

Intermonte distributes research and engages in other approved activities with respect to Major U.S. Institutional Investors ("Majors") and other Qualified Institutional Buyers ("QIBs"), in the United States, via Brasil Plural Securities LLC under SEC 15a-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

## ANALYST CERTIFICATION

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including Intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities.

Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

The analyst responsible for the report is not a) a resident of US; b) an associated person of a U.S. broker-dealer; c) supervised by a supervisory principal of a U.S. broker-dealer. This Research Report is distributed in the U.S. through Brasil Plural Securities LLC, 545 Madison Avenue, New York 10022.

## GUIDE TO FUNDAMENTAL RESEARCH

The main methods used to evaluate financial instruments and set a target price for 12 months after the investment recommendation are as follows:

- Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM)
- Comparison with market peers, using the most appropriate methods for the individual company analysed: among the main ratios used for industrial sectors are price/earnings (P/E), EV/EBITDA, EV/EBIT, price/sales.
- Return on capital and multiples of adjusted net book value are the main methods used for banking sector stocks, while for insurance sector stocks return on allocated capital and multiples on net book value and embedded portfolio value are used
- For the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB)

Some of the parameters used in evaluations, such as the risk-free rate and risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 2.5% and a risk premium of 5.0% are being used.

Frequency of research: quarterly.

Reports on all companies listed on the S&PMB40 Index, most of those on the MIBEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow.

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published.

Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period;

OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period;

NEUTRAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period;

UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period;

SELL: stock expected to underperform the market by over 25% over a 12 month period.

Prices: The prices reported in the research refer to the price at the close of the previous day of trading

## CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms.

As at 31 March 2022 Intermonte's Research Department covered 120 companies. Intermonte's distribution of stock ratings is as follows:

BUY:	16.67 %
OUTPERFORM:	55.88 %
NEUTRAL:	23.53 %
UNDERPERFORM:	03.92 %
SELL:	00.00 %

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (53 in total) is as follows:

BUY:	33.96 %
OUTPERFORM:	49.06 %
NEUTRAL:	16.98 %
UNDERPERFORM:	00.00 %
SELL:	00.00 %

## CONFLICT OF INTEREST

In order to disclose its possible conflicts of interest Intermonte SIM states that:

Within the last year, Intermonte SIM managed or co-managed/is managing or is co-managing an Institutional Offering and/or managed or co-managed/is managing or is co-managing an offering with firm commitment underwriting of the securities of the following Companies: BPER, Cybero, Luve, Seri Industrial, The Italian Sea Group, Tinexta, WIIT.

Intermonte SIM has provided in the last 12 months / provides / may provide investment banking services to the following companies: Abitare In, Aedes, Amalfi Holding (on La Doria shares), Ambientthesis, Cellularline, Creval, Cy4Gate, Esprinet, G4 and Finami (on Lu-Ve shares), GPI, Growens, Gruppo Caltagirone (in connection with roadshow activities ahead of 2022 Generali AGM), Illimity Bank, Link Mobility Group (on AMM shares), Maire Tecnimont, Neuberger Berman (on Seri Industrial shares), OVS, Sedoc (on Cybero shares), SP5 (on Guala Closures shares), Tesmec, Tinexta and WIIT.

Intermonte SIM provides investment banking services to Esprinet in connection with the non binding offer on Cellularline announced on the 7<sup>th</sup> of May 2022

Intermonte SIM is Specialist and/or Corporate Broker and/or Sponsor and/or Broker in charge of the share buy back activity of the following Companies: Abitare In, Aedes, Alkemy, Ambientthesis, Anima, Aquafil, Avio, Banca Ifis, Banca Sistema, Cattolica, Cellularline, Civitanavi Systems, Cybero, Cy4Gate, DeA Capital, El.En, Eles, Elica, Emak, Esprinet, Expert AI, Falck Renewables, Fimit - Fondo Alpha, Fine Foods, Gefran, Go Internet, Gpi, Gruppo Fos, GVS, IEG, Iervolino Entertainment, IndelB, Luve, Matica Fintec, Notorious Pictures, Nova Re SIQ, Omer, Pharmanutra, Relatech, Reply, Retelit, Sababa Security, Saes Getters, Salcef, Sciuker Frames, Seco, Servizi Italia, Sesa, Seri Industrial, Somec, Tamburi, Tinexta, Tesmec, The Italian Sea Group, Txt and WIIT.

Intermonte SIM has a contractual commitment to act as liquidity provider on behalf of third parties for the following company: Banca Sistema.

Intermonte SIM performs as a market maker for the following companies: A2A, Anima, Atlantia, Autogrill, Azimut Holding, BAMI, Banca Generali, Banca Mediolanum, Brembo, Buzzi, CNHI, Enel, ENI, Exor, Fineco, FCA, FTMI, Generali, Italgas, Iren, Intesa Sanpaolo, Leonardo, Mediobanca, Mondel, Mediaset, Pirelli&C, Prysmian, Poste, Ferrari, Saipem, Snam, STM, Tenaris, Telecom Italia, Telecom Italia sav, Terna, UBI, Unicredit, Unipol, UnipolSai.

Intermonte SIM is a member of the CBOE Europe Equities Liquidity Provider Program for the following financial instruments: A2A, Atlantia, ATSM, Autogrill, Azimut Holding, Banca Generali, Banca Mediolanum, Banco BPM, Bca Monte dei Paschi di Siena, Bca Pop Emilia Romagna, Banca Pop Sondrio, Buzzi Unicem, Buzzi Unicem rsp, Campari, CIR- Compagnie Industriali Riunite, Credito Emiliano, Danieli & C., Danieli & C. Rispo NC, Diasorin, Enel, Eni, Generali, Hera, Intesa Sanpaolo, Iren, Italgas, Italmobiliare, Leonardo, Maire Tecnimont, Mediaset, Mediobanca, Pirelli & C., Poste Italiane, Prysmian, Recordati, S.I.A.S., Saipem, Salini Impreglio, Salvatore Ferragamo, Snam, Telecom Italia, Telecom Italia rsp, Terna, Tod's, UBI Banca, Unicredit, Unipol, UnipolSai.

Intermonte SIM, through Websim and TIE, which constitute the digital division of Intermonte, acts as a Retail Investor Research Provider on the following companies: Abitare In, Aedes, Aleph Finance, Alkemy, Banca Sistema, Borgosesia 1873, B&C Speakers, Casta Diva Group, Cattolica Assicurazioni, Cellularline, Circle, Cleanb, Comer Industries, Convergence Spa, Crowdfundme, Cy4Gate, Cybero, Dh, Digital Bros, Digital Magics, Doxee, Ediliziaacrobatica Spa, Eles, Elica, Emak, Esi, Esprinet, Fabilia, Fenix Entertainment, Fiera Milano, Finlog, First Capital, Fope, Fos, Franche Umberto Marmi, Generali Assicurazioni, Giglio, Gismondi 1754, Go Internet, Gpi, H-Farm, ID-Entity, Iervolino & Lady Bacardi Entertainment, Indel B, International Care Company, Intred, Kolpinharma, Lindbergh, LVenture, Maps, Masi Agricola, Matica Fintec, Neodecortech, Nice Footwear Spa, Notorious Pictures, Nusco SPA, Nvp, Omer Spa, Orsero Group, Osai Automation System, Piaggio, Pierrel, Promotica, Reevo Spa, Relatech, Reti, Salcef Group, Sciuker Frames, Sebino, Sit Group, Sos Travel, Sourcesense, Spindox Digital Soul, Supplyncapital, Take Off, Tamburi, Tenax International, Tesmec, The Italian Sea Group, Tinexta, Tps, Trenddevice, Tribuo, Ulisse Biomed, Unidata, Vantea Smart, Websolite, WIIT.

Intermonte SIM, through Websim and TIE, which constitute the digital division of Intermonte, carries out marketing/communications on behalf of equity crowdfunding portals, Crowdfundme and the following issuers: Barlays, BNP Paribas, Cirdan, Exane, Goldman Sachs, Franklin Templeton, Leonteq, Marex, Mediobanca, SPDR, Unicredit, Vontobel, Wisdomtree.

Intermonte SIM SpA holds net long or short positions in excess of 0.5% of the overall share capital in the following issuers:

Emittente	%	Long/Short
AEDES NEW	3.7	LONG
COGEME SET SPA	1.6	SHORT
IKF	0.57	SHORT
OLIDATA	0.74	SHORT

© Copyright 2022 by Intermonte SIM - All rights reserved

It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERMONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization.

INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product.

INTERMONTE SIM is MiFID compliant - for our Best Execution Policy please check our Website [MIFID](#)

Further information is available